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Abstract
Background: Comorbidity has been shown to intensify health care utilization and to increase
medical care costs for patients with diabetes. However, most studies have been focused on one
health care service, mainly hospital care, or limited their analyses to one additional comorbid
disease, or the data were based on self-reported questionnaires instead of health care registration
data. The purpose of this study is to estimate the effects a broad spectrum of of comorbidities on
the type and volume of medical health care utilization of patients with diabetes.
Methods: By linking general practice and hospital based registrations in the Netherlands, data on
comorbidity and health care utilization of patients with diabetes (n = 7,499) were obtained.
Comorbidity was defined as diabetes-related comorbiiabetes-related comorbidity. Multilevel
regression analyses were applied to estimate the effects of comorbidity on health care utilization.
Results:  Our results show that both diabetes-related and non diabetes-related comorbidity
increase the use of medical care substantially in patients with diabetes. Having both diabeterelated
and non diabetes-related comorbidity incrases the demand for health care even more. Differences
in health care utilization patterns were observed between the comorbidities.
Conclusion: Non diabetes-related comorbidity increases the health care demand as much as
diabetes-related comorbidity. Current single-disease approach of integrated diabetes care should
be extended with additional care modules, which must be generic and include multiple diseases in
order to meet the complex health care demands of patients with diabetes in the future.
Background
Comorbidity, defined as the occurrence of one or more
chronic conditions in the same person with an index-dis-
ease, occurs frequently among patients with diabetes
[1,2]. Currently, integrated diabetes care programs focus
on diabetes-related comorbidities like cardiovascular dis-
eases, retinopathy, nephropathy and diabetic foot. How-
ever, patients with diabetes do not only have diabetes-
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related comorbidity but also have non diabetes-related
comorbidity, such as depression and musculoskeletal dis-
eases [2-5]. With the ongoing population aging of West-
ern societies, not only the number of patients with
diabetes is expected to increase, but also the number of
patients with diabetes with comorbidity. This implies that
the current single disease management approach is not
applicable to a large part of the patients with diabetes in
the future.
Comorbidity among patients with diabetes is associated
with considerable consequences for health care and
related costs [6-15]. Comorbidity has been shown to
intensify health care utilization and to increase medical
care costs for patients with diabetes. However, most stud-
ies have been focused on one health care service, mainly
hospital care [6,11,12], or limited their analyses to one
additional comorbid disease [7,11]. In addition, previous
studies on multidisciplinary health care utilization were
based on self-reported questionnaires instead of health
care registration data [9]. We elaborated on these studies
by taking into account a broad spectrum of comorbidities
and focusing on multiple health care services by linking
data of different health care registrations.
The aim of this study is to examine the impact of comor-
bidity in patients with diabetes on the use of general prac-
titioner (GP) care, medical specialist care and hospital
care. After presenting the prevalence figures of comorbid-
ity in patients with diabetes, the following questions will
be addressed: what is the effect of comorbidity on the type
and volume of health care utilization of patients with dia-
betes? And, which comorbidity pattern has the highest
additional effect?
A better understanding of the effects of comorbidity on
the type and volume of medical health care utilization is
essential to gain insight into future health care demands
of patients with diabetes.
Methods
Design
Data on comorbidity and health care utilization were
derived from three health care registrations. Firstly, data
were obtained from the second Dutch National Survey of
General Practice (DNSGP-2)[16]. The DNSGP-2 was car-
ried out in 104 general practices (including 195 General
Practitioners (GPs)) in the Netherlands in 2001. The
DNSGP-2 includes approximately 385,000 patients, with
data about 1,5 million encounters, 2,2 million prescrip-
tions of pharmaceuticals and 170,000 first time referrals
to other health care providers. Diagnoses were coded
according to the International Classification of Primary
Care (ICPC) [17]. The study population is representative
of the Dutch population regarding age, gender and type of
health care insurance [17]. Dutch GPs are the gatekeepers
for medical specialised care and nearly all non-institution-
alised patients are listed to a GP.
Secondly, information about consultations of medical
specialists were obtained from the National Register of
ambulatory care for the years 1999 until 2002 [18]. In the
Netherlands, medical specialists work in hospitals. In
2001, 108 out of the 120 hospitals in the Netherlands
have joined the National Register of ambulatory care.
Forty-five percent of the hospitals register all visits to a
medical specialist. The other hospitals register only the
first visit during a certain calendar year. Records comprise
date of birth, gender, area zip code, medical specialty and
date of consultation. In 2001, about 8,7 million consulta-
tions of medical specialists were registered in this register.
Thirdly, data were obtained from the National Medical
Register for the years 1999 until 2002 [19]. This database
has an almost complete coverage (99%) of all hospital
admissions in the Netherlands. Records comprise date of
birth, gender, area zip code, length of stay, diagnosis at
discharge and vital status at discharge. Diagnoses at dis-
charge are coded according to the International Classifica-
tion of Diseases, Ninth Revision [20]. The total number of
hospital admissions amounted to about 1,5 million in
2001.
Patient linkage
We used gender, date of birth and area zip code of the
patient as linking variables for the linkage of records in
the different registrations, since a unique identifier is not
available in the Netherlands [21]. A pilot linkage was suc-
cessfully carried out in order to evaluate the representa-
tiveness of the linkage and the resulting population [22].
The starting point of the linkage is a GP referral. On the
basis of each GP referral we searched for corresponding
records in the ambulatory care and hospital registers. We
restricted the period in the registers for each separate refer-
ral to 180 days before and 360 days after the referral date.
Linkages outside this period were excluded from the anal-
yses.
Study population
First, patients with missing values on any of the linking
variables and patients with a non-unique combination of
linking variables in the DNSGP-2 were excluded from the
analyses (n = 24,193, 6%). Subsequently, we selected
patients who had contacted their GP for diabetes mellitus
(ICPC code T90) in 2001 (n = 9,313). In addition, we
excluded patients with missing information on socioeco-
nomic status, which was indicated by highest educational
level (n = 1,814). Socioeconomic status was included as a
confounding variable. In total, 7,499 diabetes mellitus
patients were included in the analyses.BMC Health Services Research 2006, 6:84 http://www.biomedcentral.com/1472-6963/6/84
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Measures
We included the following measures of medical health
care utilization in the analysis: the number of contacts
with the GP (per year), total number of prescriptions by
the GP (per year), mean number of prescriptions per GP
contact, consultation of the medical specialist (yes/no),
the number of consultations of the medical specialist (per
year) (of those who consulted the medical specialist), hos-
pital admission (yes/no), the number of hospital admis-
sions (per year) (of those who were admitted to the
hospital), the average length of stay per hospital admis-
sion, and the total number of hospital days (per year).
Micro- and macrovascular comorbidity was defined as
chronic conditions which have a vascular relationship
with diabetes or which can be seen as vascular complica-
tions of (the treatment) of diabetes. Non-vascular comor-
bidity was defined as chronic conditions of which the
relationship with diabetes is unrelated or still not under-
stood [23], but are not the result of vascular damage.
Comorbid conditions were based on diagnosis recorded
by GPs. Diabetes-related comorbidity included the fol-
lowing chronic conditions: heart diseases (K74–K77),
stroke (K90), retinopathy (F83), nephropathy (U99) and
diabetic foot (S97). The non diabetes-related comorbidity
was defined as depression (P76), lung diseases (Chronic
Obstructive Pulmonary Disease (COPD) (R91, R95) and
asthma (R96)), musculoskeletal diseases, neurological
diseases and cancer. Musculoskeletal disease was defined
as any of the following conditions: low back pain (L02,
L03 and L86), shoulder and neck pain (L01, L08) and
osteoarthritis of knee (L13), hip (L15) or spine (L84, L89–
91). Neurological disease was defined as multiple sclero-
sis (N86), Parkinson's disease (N87) and epilepsy (N88).
Cancer was defined as non-Hodgkin disease (B74), stom-
ach cancer (D74), colon cancer (D75), oesophagus cancer
(D77), lung cancer (R84), skin cancer (S77), breast cancer
(X76), and prostate cancer (Y77).
Statistical analyses
We categorized comorbidity in two ways: 1) the presence/
absence of any comorbidity, and 2) four mutually exclu-
sive categories of no comorbidity, vascular comorbidity
only, non-vascular comorbidity only, and both vascular
and non-vascular comorbidity.
First, we compared the patient characteristics and assessed
the differences in health care utilization between the
patient groups by performing chi-square tests and t-tests
(table 1).
Subsequently, multilevel analyses were applied to esti-
mate the effects of comorbidity on health care utilization.
Multilevel analyses were used because of the two-level
structure of the data (i.e. practice level and patient level),
allowing us to adjust for variation among GP-practices
(e.g. variation regarding diabetes control and prescription
behaviour) (table 2 and 3). We estimated the effect of
comorbidity on health care utilization in three ways: 1)
the effect of the presence of any comorbidity (table 2), 2)
the effect of the type of comorbidity (vascular or non-vas-
cular) (table 2), and 3) the effect of specific comorbidity
(table 3).
The presence of any comorbidity, type of comorbidity and
specific comorbidities were coded as dummy variables. In
all multilevel analyses, we adjusted for age, gender and
educational level of the patient (all fixed effects) and GP-
practices (random effect) and the patient group without
comorbidity was used as reference group. In all multilevel
analyses, variances in the health care utilization were
assessed both at the GP practice-level and the individual
level. The size of the GP practice level variance (between
GP-practice variation) and the size of the individual-level
variance are expressed relative to the overall variance. The
effect sizes as results of the multilevel linear and logistic
regression analyses were expressed as coefficient (β) with
95% confidence intervals (CI) or as odds ratio (OR) with
the corresponding 95% CI.
Results
Of all patients referred by their GP to a medical specialist
87% could be linked to a hospital admission, an outpa-
tient treatment or an outpatient visit.
In table 1, data on patient characteristics and health care
utilization measures are listed. About 44% (n = 3,324) of
the patients with diabetes had any additional comorbid-
ity, while 56% of the patients with diabetes had no addi-
tional comorbidity (n = 4,175). The comorbid patients
were categorized into one, two and three or more comor-
bidities. Patients with diabetes without comorbidity were
younger (62.6 versus 66.9, 71.1 and 72.9 years of age),
were more likely to be male (48.4% versus 43.7%, 40.4%
and 41.2% males) and higher educated (10.5% versus
7.4%, 3.6% and 5.3% high educated patients). After spec-
ifying the comorbidity as vascular or non-vascular, signif-
icant differences in patient characteristics between the
comorbid patient groups were observed. Patients with
vascular comorbidities were more likely to be male com-
pared with the other comorbid patient groups (51.2%
males versus 39.0% and 42.5%, respectively). Patients
with both vascular and non-vascular comorbidity were on
average older compared with patients with either vascular
or non-vascular comorbidity (73.1 versus 71.5 and 64.9
years of age respectively) and more likely to be lower edu-
cated (4.0% versus 6.5% and 7.3% high educated patients
respectively).B
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Table 1: Patient characteristics and unadjusted medical health care utilization of patients with diabetes specified for absence/presence of comorbidity and type of comorbidity 
(% or mean (standard deviation (SD) (n = 7,499))
DM only DM + any comorbidity (n = 3,324) Type of comorbidity
DM + only dm-
related comorbidity
DM + only non dm-
related comorbidity
DM + both types of 
comorbidity
Number of comorbidities - 1 2 ≥3
(n = 4,175) (n = 2,419) (n = 718) (n = 187) (n = 871) (n = 1,856) (n = 597)
%/Mean (SD) %/Mean (SD) %/Mean (SD) %/Mean (SD) %/Mean (SD) %/Mean (SD) %/Mean (SD) P-value
Percentage of total (%) 55.7 32.3 9.6 2.5 11.6 24.7 8.0
Patient characteristics
Sex (% male) 48.4 43.7 40.4 41.2 51.2 39.0 42.5 0.000
Mean age (in years) 62.6 66.9 71.1 72.9 71.5 64.9 73.1 0.000
Educational level (%) #
Low 43.2 49.8 55.6 59.4 56.1 47.3 58.3 0.000
Middle 46.3 42.7 40.8 35.3 37.3 45.4 37.7
High 10.5 7.4 3.6 5.3 6.5 7.3 4.0
Mean number of comorbidities 1.11 1.13 2.34 0.000
Medical health care utilization
GP care
% of patients with GP contacts 100 100 100 100 100 100 100
Number of contacts with GP (per year) 8.9 (6.5) 13.7 (8.60) 20.8 (12.8) 28.8 (15.9) 15.0 (10.6) 14.3 (9.1) 23.2 (14.0) 0.000
% of patients with prescriptions 97.0 98.5 99.3 98.4 99.4 98.2 99.2 0.000
Number of prescriptions (per year) 18.1(16.8) 25.9 (21.0) 39.8 (31.3) 57.1 (44.2) 32.0 (25.3) 25.6 (23.0) 44.4 (33.9) 0.000
Ambulatory medical specialist care†
% of patients with consultations 12.3 23.0 30.4 38.0 17.8 26.5 33.3 0.000
Number of consultations (per year) 2.1 (1.4) 2.7 (1.7) 3.4 (2.0) 4.0 (2.3) 2.7 (1.6) 2.8 (1.8) 3.6 (2.2) 0.000
Hospital care
% of patients with hospital admission† 5.1 14.7 23.1 31.0 13.8 16.2 26.5 0.000
Number of hospital admissions (per 
year)
1.7 (1.3) 2.3 (2.1) 2.9 (2.8) 3.2 (2.3) 2.7 (2.3) 2.3 (2.3) 2.9 (2.5) 0.000
Average length of stay (per admission) 6.7 (10.6) 6.3 (7.7) 8.0 (7.5) 11.2 (11.4) 7.9 (7.8) 5.8 (7.6) 9.5 (9.1) 0.001
Total hospital days (per year) 10.7 (16.3) 14.8 (21.0) 22.4 (26.5) 31.9 (27.3) 21.1 (24.4) 14.2 (22.1) 25.3 (25.6) 0.000
DM: diabetes mellitus; GP: general practitioner. # low: none and primary school; middle: secondary school or lower and intermediate vocational training; high: higher vocational training or 
university. †= only first referrals are included in the analysis.B
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Table 2: Effect of comorbidity of patients with diabetes on medical health care utilization adjusted for age, gender, educational level and GP practice specified for type of 
comorbidity with the patient group without comorbidity as reference group (coefficient and 95% confidence interval (CI) and Odds Ratio (OR) and 95% CI (n = 7,499))
DM + any comorbidity (n = 3,324) Type of comorbidity
DM + only dm-related 
comorbidity
DM + only non dm-
related comorbidity
DM + both types of 
comorbidity
Number of comorbidities 1 (n = 2,419) 2 (n = 718) ≥3 (n = 187) (n = 871) (n = 1,856) (n = 597)
β/OR CI 95% β/OR CI 95% β/OR CI 95% β/OR CI 95% β/OR CI 95% β/OR CI 95%
GP care
No. of visits to GP (β) 3.9 (3.6, 4.3) 10.3 (9.7, 10.9) 18.0 (16.9, 19.1) 4.6 (4.1, 5.2) 4.7 (4.2, 5.1) 12.4 (11.7, 13.0)
% patients with prescriptions (OR) * * * * * *
No. of prescriptions (β) 6.9 (5.9, 7.9) 19.2 (17.6, 20.8) 35.9 (33.0, 38.7) 11.7 (10.3, 13.2) 7.0 (5.9, 8.0) 23.4 (21.7, 25.2)
Ambulatory medical specialist care†
% of patients with consultations (OR) 2.4 (2.1, 2.8) 3.7 (3.1, 4.6) 5.6 (4.0, 7.9) 1.7 (1.4, 2.1) 2.9 (2.5, 3.3) 4.3 (3.5, 5.4)
No. of consultations (β) 0.4 (0.3, 0.4) 0.8 (0.7,0.9) 1.3 (1.1, 1.5) 0.2 (0.1, 0.3) 0.5 (0.4, 0.6) 1.0 (0.8, 1.1)
Hospital care
% patients with hospital admission (OR) 3.4 (2.9, 4.2) 6.4 (5.1, 8.2) 9.8 (6.8, 14.0) 3.3 (2.5, 4.2) 3.8 (3.2, 4.6) 7.7 (6.0, 9.9)
No. of hospital admissions (β) 0.3 (0.2, 0.3) 0.6 (0.5, 0.7) 0.9 (0.8, 1.1) 0.3 (0.2, 0.4) 0.3 (0.2, 0.4) 0.7 (0.6, 0.8)
Average length of stay (β) 0.6 (0.4, 0.7) 1.4 (1.1, 1.7) 3.0 (2.5, 3.6) 0.7 (0.4, 0.9) 0.6 (0.4, 0.9) 2.1 (1.8, 2.4)
Total hospital days (β) 1.5 (1.1, 2.0) 4.5 (3.7, 5.2) 9.1 (7.8, 10.4) 2.2 (1.5, 2.8) 1.7 (1.2, 2.2) 5.9 (5.1, 6.7)
DM: diabetes mellitus; GP: general practitioner. # low: none and primary school; middle: secondary school or lower and intermediate vocational training; high: higher vocational training or 
university. †= only first referrals are included in the analysis.B
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Table 3: Effect of comorbidity of patients with diabetes on medical health care utilization adjusted for age, gender, educational level and GP practice specified by comorbidity 
with the patient group without comorbidity as reference group (coefficient and 95% confidence interval (CI) and Odds Ratio (OR) and 95% CI)
DM-related comorbidity Heart diseases 
(n = 1,096)
Stroke 
(n = 218)
Retinopathy 
(n = 63)
Nephropathy 
(n = 57)
Diabetic Foot 
(n = 204)
β/OR CI 95% β/OR CI 95% β/OR CI 95% β/OR CI 95% β/OR CI 95%
GP care
No. of visits to GP (β) 5.2 (4.74, 5.73) 3.4 (2.4, 4.4) 3.20 (1.37, 5.04) 5.6 (3.7, 7.6) 8.46 (7.42, 9.48)
% patients with prescriptions (OR) * * * * *
No. of prescriptions (β) 12.8 (11.52, 14.1) 4.1 (1.6, 6.7) 5.62 (0.90, 10.36) 12.1 (7.2, 17.0) 20.88 (18.23, 23.54)
Ambulatory medical specialist care†
% of patients with consultations (OR) 1.7 (1.5, 2.1) 2.0 (1.5, 2.9) 1.4 (0.8, 2.7) 1.0 (0.5, 1.9) 1.0 (0.7, 1.5)
No. of consultations (β) 0.4 (0.3, 0.4) 0.4 (0.2, 0.6) -0.2 (-0.1, 0.5) -0.1 (-0.5, 0.2) 0.0 (-0.2, 0.2)
Hospital care
% patients with admission (OR) 2.6 (2.2, 3.2) 2.8 (2.0, 4.1) 1.9 (1.00, 3.7) 0.9 (0.4, 1.9) 1.4 (0.9, 2.1)
No. of hospital admissions (β) 0.4 (0.3, 0.4) 0.4 (0.2, 0.5) 0.3 (0.1, 0.6) 0.2 (-0.1, 0.4) 0.1 (-0.0, 0.2)
Average length of stay (β) 0.9 (0.7, 1.1) 1.5 (1.0, 2.0) 0.7 (-0.2, 1.6) -0.2 (-1.1,0.7) 0.8 (0.3, 1.3)
Total hospital days (β) 3.1 (2.5, 3.7) 3.3 (2.1, 4.4) 2.1 (0.0, 4.3) 0.8 (-1.5, 3.1) 2.4 (1.2, 3.6)
Non DM-related comorbidity Depression 
(n = 295)
Neurological diseases 
(n = 69)
Musculoskeletal Diseases
(n = 1,722)
Lung Diseases 
(n = 531)
Cancer 
(n = 206)
β/OR CI 95% β/OR CI 95% β/OR CI 95% β/OR CI 95% β/OR CI 95%
GP care
No. of visits to GP (β) 6.8 (5.9, 7.6) 4.1 (2.4, 5.9) 4.1 (3.7, 4.5) 5.3 (4.6, 5.9) 5.9 (4.9, 6.9)
% patients with prescriptions (OR) * * * * *
No. of prescriptions (β) 12.9 (10.6, 15.1) 8.0 (3.5, 12.5) 4.2 (3.2, 5.3) 15.3 (13.6, 17.0) 3.4 (0.8, 6.1)
Ambulatory medical specialist care†
% of patients with consultations (OR) 1.1 (0.8, 1.5) 1.0 (0.5, 1.8) 3.6 (3.1, 4.1) 1.2 (1.0, 1.5) 1.3 (0.9, 1.9)
No. of consultation by specialist (β) 0.2 (0.1, 0.3) 0.1 (-0.2, 0.3) 0.6 (0.6, 0.7) 0.3 (0.2, 0.4) 0.4 (0.2, 0.5)
Hospital care
% patients with admission (OR) 1.3 (0.9, 1.9) 1.5 (0.8, 2.9) 3.8 (3.2, 4.4) 1.2 (0.9, 1.6) 1.8 (1.2, 2.7)
No. of hospital admissions (β) 0.1 (0.0, 0.2) 0.0 (-0.3, 0.2) 0.3 (0.3, 0.4) 0.1 (0.1, 0.2) 0.4 (0.2, 0.5)
Average length of stay (β) 0.5 (0.1, 0.9) 0.5 (-0.3, 1.4) 0.9 (0.7, 1.1) 0.4 (0.0, 0.7) 0.5 (0.0,1.0)
Total hospital days (β) 1.5 (0.5, 2.6) 0.1 (-1.9, 2.2) 2.3 (1.8, 2.7) 1.47 (0.7, 2.2) 2.4 (1.2, 3.6)
DM: diabetes mellitus; GP: general practitioner *= ORs for getting pharmaceuticals prescribed can not be calculated due to the high percentages of patients who get pharmaceuticals prescribed; 
† = only first referrals are included in the analysis.BMC Health Services Research 2006, 6:84 http://www.biomedcentral.com/1472-6963/6/84
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Medical health care utilization
A clear gradient was observed between the number of
comorbidities and the increase of health care utilization,
with the exception of the percentage of patients with pre-
scriptions, which was in all patient groups almost 100%
(table 1). No large differences were observed in the use of
GP care between patients with either vascular comorbidity
or non-vascular comorbidity. Patients with both types of
comorbidity visit their GP more frequently than patients
with either vascular comorbidity or non-vascular comor-
bidity (23.2 vs. 15.0 and 14.3 GP contacts respectively).
The same pattern was observed for the total number of
prescriptions per year.
Fewer patients with diabetes only consulted the medical
specialist (12.3%) compared to the patient groups with
vascular comorbidity, non-vascular comorbidity or both
(17.8%, 26.5% and 33.3% respectively). The same pattern
was observed for the mean number of consultations with
the medical specialist, for being admitted to the hospital,
the mean number of hospital admissions and for the total
number of hospital days. The average length of stay in the
hospital for patients with non diabetes-related comorbid-
ity was relatively shortest (5.8 days).
Multilevel modeling showed that 16% of the total vari-
ance in the number of GP contacts was related to the GP
practice level, and that 84% occurred at the individual
level (not tabulated). This means that the number of GP
contacts of patients with diabetes within GP-practices are
correlated, and as a consequence, that using one-level lin-
ear regression models will lead to less valid estimates. Var-
iance at the GP practice level was also substantial in the
number of GP prescriptions (11%) and having consulted
the medical specialist (8%) but diminished in other
health care utilization measures, varying from 5%
(number of consultations with the medical specialist) till
1% (average length of stay).
In the multilevel multivariate analyses, a strong gradient
was observed between the number of comorbidities and
health care utilization measures after adjustment for age,
gender, educational level and GP-practice (table 2). An
increasing number of comorbidities resulted in an
increase in health care utilization for all measures.
For patients with vascular comorbidity or non-vascular
comorbidity, no differences were found for the number of
GP visits (4.6 and 4.7 respectively), number of hospital
admissions (0.3 and 0.3 respectively) and average length
of stay in the hospital (0.7 days and 0.6 days respectively).
Patients with both vascular and non-vascular comorbidity
have the highest health care utilization with respect to
both GP care, medical specialist care and hospital care.
Table 3 shows that each specific comorbidity increased
the use of GP care substantially, especially diabetic foot
(8.5 additional GP contacts and 20.9 additional prescrip-
tions (mainly bandages)), compared with patients with
diabetes without comorbidity.
The effects of comorbidity on the use of medical specialist
care differ between the specific comorbidities. For retinop-
athy, nephropathy, diabetic foot and neurological dis-
eases no significant differences were observed in the
number of consultations with the medical specialist com-
pared with patients with diabetes without comorbidity. In
addition, the ORs for having consulted the medical spe-
cialist differed significantly only for heart diseases, stroke
and musculoskeletal diseases as compared with the refer-
ence group (OR = 1.7, OR = 2.0 and OR = 3.6 respec-
tively).
Patients with diabetes, having a heart disease or stroke as
a comorbid disease, showed the relatively largest increase
in hospital care (3.1 and 3.3 additional hospital days
respectively). The average length of stay was significantly
higher in most of the comorbidities, with the exception of
retinopathy, nephropathy and neurological diseases. For
heart diseases, stroke, musculoskeletal diseases, medical
health care utilization was significant increase compared
with the reference group for all health care measures. The
other comorbid diseases resulted in a significant increase
of health care utilization for only two or three health care
utilization measures.
Discussion
Not surprisingly, a strong correlation was observed in this
study between the number of comorbidities and the use
of GP care, ambulatory specialist care and hospital admis-
sions. However, we found no systematic differences
between patients with either vascular or non-vascular
comorbidity. Patients with both vascular and non-vascu-
lar comorbidity showed the highest health care utilization
pattern. This is mainly caused by the higher number of
comorbidities in this patient group.
Our results demonstrated that patients without comor-
bidity use little care. The large impact on health care utili-
zation of patients with diabetes occurs when diabetes is
included in a constellation of vascular and non-vascular
comorbidities. Therefore, health care providers should
routinely monitor patients with diabetes with respect to
comorbidity. Case-finding protocols as mentioned by
Gijsen et al. [8], should be developed and implemented in
integrated diabetes care programs.
Moreover, our results demonstrated that non-vascular
comorbidities are as important utilization drivers as vas-
cular comorbidities. In addition to the beneficial effects ofBMC Health Services Research 2006, 6:84 http://www.biomedcentral.com/1472-6963/6/84
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it on the quality of life of not having any comorbidity [8],
prevention of comorbidity can possibly also curb the
growing demands for health care. Until now, prevention
in integrated diabetes care programs focuses mainly on
micro- and macrovascular comorbidity. Our study shows
that this focus is too limited, since additional non-vascu-
lar comorbidities in patients with diabetes increase the
health care utilization as much as vascular comorbidities.
Different comorbid conditions have different effects on
health care utilization. Diabetic foot results in a large
increase in the use of GP care, but not in the use of medi-
cal specialist care and hospital care. Coronary heart dis-
eases, stroke, depression, musculoskeletal diseases and
cancer result in a substantially increase in both GP care,
medical specialist care and hospital care. Our finding that
the average length of stay in the hospital increases in most
comorbidities, is in accordance with findings from other
studies [24,25].
Limitations of the study need to be considered in inter-
preting the results. Firstly, we obtained data about health
care utilization by medical record linkage of different reg-
istrations, which introduced some selection bias. Linkage
probabilities between older and younger patients differ
because of different rates of changes of address [26]. Older
people move less often than younger people and therefore
have higher linkage probabilities since area zip code is
one of the linkage variables. Therefore the hospital utiliza-
tion of the younger patients, i.e. the patient group with
diabetes only, could be underestimated.
Secondly, the number of consultations by the medical
specialist in the linkage is an underestimation of the
actual number of consultations, since only 45% of the
hospitals in the National Ambulant Register register all
consultations. Since this inaccuracy in the registration of
consultations to the medical specialist applies for all
patient groups, it is not likely that this has biased our
results.
Thirdly, for a large number of patients information on
educational level was missing and they were therefore
excluded from the analyses. Patients with missing data on
educational level might differ from the included patients,
which may have influenced our results. However, addi-
tional analyses showed that the health care utilization of
patients with unknown educational level did not differ
from the patients with known educational level.
Fourth, the prevalence's of retinopathy and nephropathy
are substantially lower than observed in another study
[27]. A reason for this underregistration could be that
retinopathy and nephropathy are not registered ade-
quately in the GP records, since these vascular comorbid-
ities are often treated and registered in integrated care
programs and resulting in suboptimal registration in the
GP records. This underestimation of the number of
patients with retinopathy and nephropathy might lead to
an underestimation of the effects of these vascualar
comorbidities on GP care, medical specialist care and hos-
pital care.
In our analyses, we focused on medical care only. Future
research should also include long-term care, e.g. home
care, nursing home care and rehabilitation care, in order
to fully understand the effects of comorbidity.
Conclusion
Non-vascular comorbidities are as important utilization
drivers as vascular comorbidity for patients with diabetes,
while patients without comorbidity use little care. These
results underline the importance of primary and second-
ary prevention of all comorbidity in patients with diabe-
tes.
Our results demonstrated also that the number of comor-
bidities is a strong predictor for the volume of medical
health care utilization and support the increasing interest
in specific patterns of comorbidity in clinical practice
[9,28]. Together with the ongoing aging of the Dutch pop-
ulation and the increase in the number of patients with
comorbidity, this may have important implications for
integrated diabetes care programs in the Netherlands.
From a public health perspective, the sum score of the
number of comorbidities is a strong tool in predicting the
future health care utilization of patients with diabetes.
Current single disease management approach is not suita-
ble for a large part of the patients with diabetes. Current
diabetes care programs must be extended to include addi-
tional care modules, which must be generic and include
multiple chronic diseases. Perhaps in the long term, cur-
rent diabetes care programs must be integrated with other
chronic diseases care programs. The results of the first tri-
als in this area are promising [29], and these integrated
chronic care programs will be more equipped to meet the
complex health care demands of patients with diabetes
and to reduce the existing gap between needs of patients
with diabetes and the supply of diabetes care in the future.
From a public health perspective, the sum score of the
number of comorbidities in patients with diabetes
appears to be a strong predictor in estimating future
health care demands.
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